BACKGROUND Effects of orally administered daytime melatonin on novelty induced behaviors and spatial working memory in mice were evaluated using the open field, the Y maze and the radial arm maze. PURPOSE To ascertain the possible nootropic and/or central excitatory or inhibitory effects of daytime oral melatonin in mice. METHODS Adult male mice from our colony, assigned to three and four g...

Abstract [ 99m Tc] fonturacetam hydrazide was radiosynthesized to assess neuropsychiatric disorders by targeting the brain. The nootropic drug labeled with technetium-99m, and factors affecting labeling yield were studied. At optimum conditions, radiocomplex obtained at a high radiochemical (98.9%) stable in saline for up 36 h serum more than 24 h. Labeled characterized assessed silico. Biodist...

OBJECTIVE To investigate the effect of combined therapy of exercise and nootropic agent on cognitive function in a focal cerebral infarction rat model. METHOD Forty 10-week old male Sprague-Dawley rats were subjected to photothrombotic cerebral infarction of the left parietal lobe. All rats were randomly divided into 4 groups: group A was photothrombotic cerebral infarction rats without any t...

Nefiracetam (DM-9384) is a new pyrrolidone nootropic drug being developed for the treatment of Alzheimer's type and poststroke vascular-type dementia. Because the cholinergic system plays an important role in cognitive functions and Alzheimer's disease dementia, the present study was conducted to elucidate the mechanism of action of nefiracetam and aniracetam on neuronal nicotinic acetylcholine...

BACKGROUND Numerous studies have looked at the potential benefits of various nootropic drugs such as Ginkgo biloba extract (EGb761®; Tanakan®) and piracetam (Nootropyl®) on age-related cognitive decline often leading to inconclusive results due to small sample sizes or insufficient follow-up duration. The present study assesses the association between intake of EGb761® and cognitive function of...

Nicotinic acetylcholine receptors and N-methyl-D-aspartate (NMDA) receptors are known to be down-regulated in the brain of patients with Alzheimer's disease. It was previously shown that the nootropic drugs nefiracetam and galantamine potentiate the activity of both nicotinic and NMDA receptors. We hypothesized that donepezil, a nootropic with a potent anticholinesterase activity, might also af...